- Home
- CLDI vs CGTX Comparison
CLDI vs CGTX Comparison
Compare CLDI & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- CGTX
- Stock Information
- Founded
- CLDI 2014
- CGTX 2007
- Country
- CLDI United States
- CGTX United States
- Employees
- CLDI N/A
- CGTX N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- CLDI Health Care
- CGTX Health Care
- Exchange
- CLDI Nasdaq
- CGTX Nasdaq
- Market Cap
- CLDI 35.2M
- CGTX 30.0M
- IPO Year
- CLDI N/A
- CGTX 2021
- Fundamental
- Price
- CLDI $1.05
- CGTX $0.58
- Analyst Decision
- CLDI Strong Buy
- CGTX Strong Buy
- Analyst Count
- CLDI 3
- CGTX 6
- Target Price
- CLDI $16.67
- CGTX $8.30
- AVG Volume (30 Days)
- CLDI 2.7M
- CGTX 809.4K
- Earning Date
- CLDI 03-14-2025
- CGTX 03-25-2025
- Dividend Yield
- CLDI N/A
- CGTX N/A
- EPS Growth
- CLDI N/A
- CGTX N/A
- EPS
- CLDI N/A
- CGTX N/A
- Revenue
- CLDI N/A
- CGTX N/A
- Revenue This Year
- CLDI N/A
- CGTX N/A
- Revenue Next Year
- CLDI N/A
- CGTX N/A
- P/E Ratio
- CLDI N/A
- CGTX N/A
- Revenue Growth
- CLDI N/A
- CGTX N/A
- 52 Week Low
- CLDI $0.58
- CGTX $0.34
- 52 Week High
- CLDI $16.80
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- CLDI 45.04
- CGTX 40.43
- Support Level
- CLDI $1.16
- CGTX $0.57
- Resistance Level
- CLDI $1.30
- CGTX $0.65
- Average True Range (ATR)
- CLDI 0.24
- CGTX 0.05
- MACD
- CLDI 0.01
- CGTX -0.01
- Stochastic Oscillator
- CLDI 40.10
- CGTX 9.46
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.